Feature stories
2009
October 01, 2009
Easing the pain of cats and dogs
An innovative new Novartis product brings fast, effective relief of pain and inflammation for pets. Onsior, launched in Europe, is the first medication of its class for cats and dogs. The range of dosing options offer convenience for veterinarians and pet owners.
Read the article (for non-US residents only)
September 08, 2009
Novartis marks 20-year commitment in the fight against leprosy
The once-dreaded disease leprosy is on the brink of elimination, but the fight goes on. Novartis commemorates 20 years of helping deliver free care, drugs and rehabilitation in India.
July 22, 2009
Novartis addresses climate change
World leaders are focused on climate change and Novartis is, too. Our cutting-edge energy efficiency strategy is a driving long-term success for the environment and for our business.
May 20, 2009
Life-saving research rewarded
Scientists who developed Novartis Coartem and Glivec receive 2009 "European Inventor of the Year" awards.
April 24, 2009
Novartis in the fight against malaria
April 25 is World Malaria Day, an opportunity to reflect on the progress made in finding sustainable solutions for malaria.
March 31, 2009
A Revolutionary Collaboration
With declining efficacy and resistance to existing sheep worm treatments on the rise, Novartis Animal Health worked together with sheep farmers and veterinarians to develop an unparalleled new treatment.
March 19, 2009
Novartis in the fight against tuberculosis
As World TB Day on March 24 raises global awareness, Novartis remains a committed partner in the struggle.
February 27, 2009
A rare opportunity
The challenges of developing products in rare diseases are many - but no obstacle for Novartis Development teams.
February 04, 2009
Meeting healthcare needs in emerging markets
Novartis is working to expand its offering in emerging markets including Brazil, Russia, India and China.
About Novartis
We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.
Our products
We have a broad healthcare portfolio.